Alpha-1 antitrypsin deficiency (AATD) is a rare genetic disease that creates multiple unique phenotypes of chronic obstructive pulmonary disease. While bronchospasm, cough, dyspnea, and sputum production all occur with AATD, the phenotypic differences require a computed tomographic (CT) scan to ...
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
Alpha1-Proteinase Inhibitor (Human), ZEMAIRA® is indicated to raise the plasma level of alpha1-proteinase inhibitor (A1-PI) in patients with A1-PI deficiency and related emphysema.
The application relates to methods of treatment and treatment regimens for Alpha-1 Antitrypsin deficiency (AATD) and the conditions, manifestations, and diseases caused by AATD, by the administration of one or more expression-inhibiting oligomeric compounds having a nucleobase sequence complementary to a...
The pathophysiology of alpha 1-antitrypsin (AAT) deficiency and the use of alpha 1-proteinase inhibitor therapy in the management of emphysema caused by AAT deficiency are described. AAT deficiency is the most common genetic cause of liver disease in children and emphysema in adults. However, not...
Determining physicians’ awareness about alpha-1 antitrypsin (AAT) deficiency (AATD) may help to explain the discrepancy between the observed and expected number of patients diagnosed with this disease. This study was designed to assess the opinions on knowledge, practice pattern and attitude regarding...
Bella, Abdelhaleem M EMcElvaney, Noel GExpert Opinion on Orphan DrugsOliver JMcElvaney, Abdelhaleem M EBella, Noel GMcElvaney. (2015) α-1 antitrypsin deficiency: current and future treatment options. Expert Opinion on Orphan Drugs 3 , 5-14 /...
Bronchodilators form the backbone of symptom- atic treatment, and the improved long-acting β2-agonists and anticholinergics, possibly in combination, provide the best form of bronchodilator therapy for COPD, with the additional effect of reducing the exacerbation rate.1 The addition of inhaled ...